Abstract
Background The proportion of double vaccinated cases during measles outbreaks in England has increased since 2010, especially among teenagers and young adults. Possible explanations include: rare infections in vaccinated individuals who did not gain immunity upon vaccination, made more common as the proportion of the population born before vaccination decreases; or waning of vaccine-induced immunity, which would present new challenges for measles control in near elimination settings.
Methods To assess explanations for observed dynamics, we used a mathematical model stratified by age group, region and vaccine status, fitted to case data reported in England from 2010 to 2019. We evaluated whether models with or without waning were best able to capture the temporal dynamics of vaccinated cases in England.
Findings Only models with waning of vaccine-induced immunity captured the number and distribution by age and year of vaccinated cases. The model without waning generated more single-vaccinated cases, and fewer double-vaccinated cases above 15 years-old than observed in the data (median: 73 cases in simulations without waning, 202 in the data, 187 when waning was included). The estimated waning rate was slow (95% credible interval: 0.036% to 0.044% per year in the best fitting model), but sufficient to increase measles burden because vaccinated cases were almost as likely to cause onwards transmission as unvaccinated cases (95% credible interval for risk of onwards transmission from vaccinated cases was only 7% to 21% lower relative to unvaccinated cases).
Interpretation Measles case dynamics in England is consistent with waning of vaccine-induced immunity. Since measles is highly infectious, a slow waning leads to a heightened burden, with an increase in the number of both vaccinated and unvaccinated cases. Our findings show that the vaccine remains protective against measles infections for decades, but breakthrough infections are increasingly likely for individuals aged 15 and older.
Funding National Institute for Health Research; Wellcome Trust.
Evidence before this study We searched PubMed up to February 29, 2024, with no language restrictions using the following search terms: (measles) AND (“secondary vaccine failure” OR waning) AND (antibody OR “vaccine effectiveness”), and excluded studies that focused on waning of maternal antibodies in infants. We found evidence of waning of antibody concentration in young adults from laboratory data, but this may not translate into a loss of protection against infection. We also found estimates of vaccine effectiveness per age group from statistical analysis that used the total number of cases across various outbreaks rather than transmission dynamics. We did not identify any study estimating waning rate of measles vaccine from recent measles case dynamics.
Added value of this study Our study uses measles case data from England, reported between 2010 and 2020. We show that the transmission dynamics in that time period was consistent with a waning of vaccine-induced immunity, making infection in young adults more common. We estimated that transmission from vaccinated cases was only slightly less common than transmission from unvaccinated cases. The increase in vaccinated cases and transmission from vaccinated cases increased the burden of measles in near-elimination settings.
Implications of all the available evidence Our study shows that measles cases caused by waning of immunity are becoming more common. As the proportion of the overall population vaccinated against measles increases, and vaccine coverage dropped in many countries near elimination between 2020 and 2022, large outbreaks become more likely. Close monitoring of double-vaccinated cases is needed to assess their ability to cause onward transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AR was supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Modelling and Health Economics, a partnership between the UK Health Security Agency, Imperial College London and LSHTM (grant code NIHR200908). The views expressed are those of the author(s) and not necessarily those of the NIHR, UK Health Security Agency or the Department of Health and Social Care. AMS. is funded by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation (NIHR200929), a partnership between UK Health Security Agency and the London School of Hygiene and Tropical Medicine. AJK. was supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (206250/Z/17/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is a secondary analysis of data collected as part of routine surveillance of measles outbreaks in England. The research was approved by the London School of Hygiene and Tropical Medicine Research Ethics Committee (reference number 15735).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The individual-level case data was collected by UKHSA and cannot be shared publicly. The code used to generate the fits, simulations and figures presented in the paper is shared in a Github repository (https://github.com/alxsrobert/measles_england_sir). This repository contains the model fits generated using the case data, the stochastic simulations, and all population and coverage data used in the analysis. In order to make this study as reproducible as possible, we generated a simulated linelist and included it in the Github repository, so readers can generate model fits on the simulated datasets.
